According to Section 52b (3e) and (3f) AMG, the manufacturing sites of the active substances actually used to manufacture the medicinal product must be reported to the BfArM.

In addition, this information must be made available to the BfArM on the basis of Section 130a (8a) and (8b) SGB V. The data can be recorded and submitted in a quality-assured manner via the portal.